Abstract
Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease,96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a "limited" status. with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / secondary
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / radiotherapy*
-
Cause of Death
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Follow-Up Studies
-
Humans
-
Infusions, Intravenous
-
Leukopenia / etiology
-
Lung / radiation effects*
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy*
-
Neoplasm Staging
-
Radiation Pneumonitis / etiology
-
Remission Induction
-
Survival Rate
-
Thrombocytopenia / etiology
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Phytogenic
-
Etoposide
-
Cyclophosphamide
-
Cisplatin